Literature DB >> 6158478

Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension.

F R Crantz, S L Swartz, N K Hollenberg, T J Moore, R G Dluhy, G H Williams.   

Abstract

We compared vascular and hormonal responses to teprotide (SQ 20,881) and captopril (SQ 14,225) in patients with normal renin essential hypertension given a 10 mEq sodium diet. In 10 patients receiving SQ 20,881, significant changes occurred in diastolic blood pressure (DBP, -13 +/- 2.5 mm Hg), angiotensin II (-7.1 +/- 2.1 pg/ml), and plasma renin activity (PRA, +6.6 +/- 1.9 ng/ml/hr) (p < 0.01 in all cases). Twenty-one patients receiving SQ 14,225 had significant changes in mean DBP (-18 +/- 1.5 mm Hg), angiotensin II (-6.6 +/- 1.5 pg/ml), and PRA (+7.8 +/- 2.4 ng/ml/hr) (all p values < 0.01). In spite of a significantly greater hypotensive response (p < 0.02), patients receiving SQ 14,225 showed increments in PRA and decrements in angiotensin II that did not differ significantly from those seen after SQ 20,881. Moreover, there was a significant change in plasma kinins in patients receiving SQ 20,881 (+2.0 +/- 0.9 ng/ml, p < 0.01) but no change in kinins in patients receiving SQ 14,225 (0.0 +/- 0.1, ns). We conclude that there are important differences in the mechanism mediating the hypotensive response to SQ 20,881 and SQ 14,225 in normal renin essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6158478     DOI: 10.1161/01.hyp.2.5.604

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  4 in total

Review 1.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

Review 2.  Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors.

Authors:  B Waeber; L Juillerat-Jeanneret; J F Aubert; M Schapira; J Nussberger; H R Brunner
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 3.  Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?

Authors:  M P Sambhi; H Gavras; J I Robertson; W M Smith
Journal:  West J Med       Date:  1993-03

4.  A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm.

Authors:  T C Li Kam Wa; E D Cooke; P Turner
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.